Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...

—For medical teams tasked with caring for patients with diffuse large B-cell lymphoma, progression or relapse that involves the central nervous system can be extremely challenging and potentially life ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this ...

Refractory and relapsed DLBCL both present several treatment challenges, but available and upcoming options may help improve outcomes. Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.